Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS HPMC capsule
Drug: BIBR 1048 MS gelatine capsule

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02170597

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS capsule formulation A
Drug: BIBR 1048 MS capsule formulation B
Drug: BIBR 1048 MS powder plus solution
Drug: Pantoprazole

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02170805

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02170571

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: BIBR 1048 capsule

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT02170935

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS
Drug: Ranitidine

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02170792

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Phase 3

Completed

Conditions: Percutaneous Coronary Intervention
Atrial Fibrillation

Interventions: Drug: Warfarin 3mg
Drug: Dabigatran Etexilate 110mg
Drug: Dabigatran Etexilate 150mg
Drug: Clopidogrel or Ticagrelor
Drug: Aspirin
Drug: Warfarin 5mg
Drug: Warfarin 1mg

First Posted Date: 2014-06-17

Last Posted Date: 2018-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2725

Registration Number: NCT02164864

Locations: 🇫🇷
CLI du Pont de Chaume, Montauban, France
🇨🇿
Hospital Jihlava, Jihlava, Czechia
🇩🇪
Klinikum Coburg gGmbH, Coburg, Germany

and more 415 locations

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004

First Posted Date: 2014-06-11

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 17

Registration Number: NCT02161432

Locations: 🇩🇪
1307.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: BI 187004

First Posted Date: 2014-05-30

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT02150824

Locations: 🇩🇪
1307.4.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪
1307.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
🇩🇪
1307.4.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

Completed

Conditions: Hemorrhage
Atrial Fibrillation

Interventions: Drug: Dabigatran 75 mg
Drug: Dabigatran 150 mg

First Posted Date: 2014-05-29

Last Posted Date: 2016-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 191

Registration Number: NCT02149303

Locations: 🇺🇸
1160.200.01 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States
🇺🇸
1160.200.05 Boehringer Ingelheim Investigational Site, Stony Brook, New York, United States
🇺🇸
1160.200.06 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

and more 2 locations

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Nintedanib (BIBF 1120)
Drug: Placebo
Drug: BSC

First Posted Date: 2014-05-29

Last Posted Date: 2017-07-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 768

Registration Number: NCT02149108

Locations: 🇵🇹
1199.52.3505 Boehringer Ingelheim Investigational Site, Loures, Portugal
🇧🇪
1199.52.3204 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇺🇸
1199.52.0108 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 126 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy